Aspirin, Genes, and Dementia: A Surprising Protective Link

Imagine a familiar, pantry-shelf pill suddenly suggesting it could alter the course of one of medicine's toughest problems. That is the provocative possibility emerging from a genetic re-analysis of a large aspirin trial: low-dose aspirin appears associated with a markedly lower dementia rate in a subset of older adults defined by their platelet-related genes. The catch is this benefit may come at a cost — a clear rise in serious bleeding events.

Platelet genes point to a narrow, testable effect

Researchers from Monash University dug back into genetic data from more than 13,500 participants in the ASPREE Trial, which originally examined aspirin's role in preventing cardiovascular events and dementia among healthy older adults. By computing genetic scores tied to a range of biological traits, the team was hunting for inherited differences that might explain why aspirin worked for some people and not others.

The strongest signal tracked to genes associated with platelet count. When participants were ranked by this platelet genetic score, those in the top 20 percent who had been randomized to daily low-dose aspirin developed dementia at about 1 percent, compared with 3.3 percent in that high-score group given placebo. That is roughly a 70 percent relative reduction in dementia risk, though the absolute difference amounts to 2.3 percentage points, equivalent to roughly 23 fewer dementia cases per 1,000 people treated.

Numbers like '70 percent' grab headlines. But context matters. The effect was concentrated in a genetically defined subgroup. Across the whole trial, aspirin had not lowered dementia risk when everyone was considered together, a result that originally tempered enthusiasm for aspirin as a dementia preventive.

Benefit shadowed by bleeding — a thorny trade-off

Good news on memory. Less good news on bleeding. In that same high platelet-score subgroup, major bleeding occurred in 4.4 percent of aspirin recipients versus 2.1 percent on placebo. Translating that into population terms, the excess bleeding risk is again about 23 additional major bleeds per 1,000 people. Two clear outcomes. Two very different consequences.

Why platelets? These small, sticky cells are central to blood clotting, and prior work has linked platelet activation and aggregation to processes implicated in dementia. What remained uncertain was whether inherited differences in platelet biology might alter dementia pathways. The Monash team says their finding steers attention away from well-known genetic suspects in Alzheimer disease and toward platelet mechanics as a potentially meaningful avenue for prevention research.

The study does not prescribe a change in clinical practice. It instead offers a testable hypothesis: if the signal is real, a prospective trial that enrolls people based on the platelet genetic profile could confirm whether aspirin's apparent cognitive benefit outweighs its bleeding harm for that group.

People should not start taking aspirin for dementia prevention without consulting their doctor.

Public-health stakes are high. Dementia Australia estimates about 446,500 Australians were living with dementia in 2026, with projections exceeding one million by 2065. Globally, the burden is already massive and growing. A cheap, generic drug that safely reduced dementia risk even modestly for a defined subgroup would be an important tool. But safety is non-negotiable, and the trade-offs must be measured in solid, prospective trials.

Methodologically, the analysis leveraged polygenic scores and the randomized structure of ASPREE to look for treatment effect heterogeneity. That is, the researchers asked: does the impact of aspirin differ by inherited biology? The platelet score popped up as the most consistent modifier. Still, replication is essential. Genetic subgroups can be idiosyncratic, and findings that emerge from secondary analyses need independent confirmation before informing practice.

Expert Insight

'This study is the kind of nudge the field needs,' says Dr Ana Morales, a clinical neurologist and prevention researcher not involved in the work. 'It reminds us that average effects can hide meaningful benefits in subgroups. But it also underlines the potency of unintended harms when a preventive strategy is applied universally. The next step is a focused trial designed around the genetics, with bleeding outcomes as a co-primary endpoint.' Her point lands simply: science must balance promise with prudence.

Conclusion

The Monash analysis opens an intriguing door. A familiar medication, long dismissed for dementia prevention in broad populations, might help a genetically defined minority. Platelet biology has moved from the periphery to the center of a new hypothesis. Confirmation will require purpose-built trials and careful risk-benefit evaluation. Until then, aspirin remains a drug that can help and harm, depending on who takes it and why. Personalized prevention is the goal. Evidence is the path.